Table 1.
Baseline clinical characteristics of the subjects.
| Total (n = 107) | Group A (n = 53) | Group B (n = 54) | P | |
|---|---|---|---|---|
| Male, n (%) | 64 (59.8) | 33 (62.3) | 31 (57.4) | 0.694 |
| Age, years | 51 ± 13.4 | 53 ± 12.9 | 49 ± 13 | 0.134 |
| Serum potassium, mmol/L | 5.57 ± 0.27 | 5.57 ± 0.26 | 5.58 ± 0.27 | 0.081 |
| CKD staging | ||||
| Stage 3 CKD, n (%) | 31 (29) | 13 (24.5) | 18 (33.3) | 0.603 |
| Stage 4 CKD, n (%) | 42 (39.3) | 22 (41.5) | 20 (37) | 0.602 |
| Stage 5 CKD, n (%) | 34 (31.8) | 18 (34) | 16 (29.6) | 0.385 |
| Serum creatinine, mg/dL | 3.31 ± 1.57 | 3.40 ± 1.55 | 3.21 ± 1.59 | 0.438 |
| eGFR, mL/minute/1.73 m2 | 24.2 ± 13 | 23.2 ± 13 | 25.2 ± 13 | 0.4 |
| Hypertension, n (%) | 89 (83.2) | 43 (81.1) | 46 (85.2) | 0.614 |
| Diabetes, n (%) | 16 (15) | 11 (20.8) | 5 (9.3) | 0.097 |
| Hemoglobin, g/dL | 11.30 ± 1.92 | 11.21 ± 2.18 | 11.39 ± 1.63 | 0.851 |
| ACEIs/ARBs, n (%) | 54 (50.5) | 22 (41.5) | 32 (59.3) | 0.068 |
| β-receptor blockers, n (%) | 28 (26.2) | 18 (34) | 10 (18.5) | 0.081 |
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.